This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 7, 2012, 5:00 pm ET
John Crowley – Chairman, CEO
Bradley Campbell – Chief Business Officer
Chip Baird – CFO
David Lockhart – Chief Scientific Officer
Ritu Baral – Canaccord
Anupam Rama – JP Morgan
Joseph Schwartz – Leerink Swann
Kim Lee - ThinkEquity
Good day, ladies and gentlemen, and welcome to the Amicus Therapeutics second quarter 2012 results conference call. At this time, all participants are in a listen-only mode and later, we will conduct a question and answer session and instructions will be given at that time. (Operator instructions). This call is being recorded. I would now like to introduce your host for today's conference, Sara Pelligrino. Now you may begin.
Good afternoon and thank you for joining our conference call to discuss our second quarter 2012 financial results. Speaking on today's call we have John Crowley, our Chairman and Chief Executive Officer, Bradley Campbell, our Chief Business Officer, David Lockhart, our Chief Scientific Officer, and Chip Baird, our Chief Financial Officer.
They are all available to participate in the Q&A session, as well. Pol Boudes, our Chief Medical Officer, is on vacation this week.
Today's prepared remarks coincide with the slide presentation that is now available on our corporate website at www.amicusrx.com. The slides are located in the Investors section under Events and Presentations right below the webcast link.
On Slide 2, we have a reference to forward-looking statements in this conference within the meaning of the Private Securities Reform Act of 1995 relating to the business, operations and financial conditions of Amicus including but not limited to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products, the projected cash position for the company.